Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01139827

Enrollment

178

Registered

2010-06-09

Start date

2009-09-30

Completion date

2010-02-28

Last updated

2010-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk

Keywords

atherosclerosis, inflammation, hsCRP, Framingham risk score, positron emission tomography, inflammation in FDG-PET

Brief summary

Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk. The investigators are examining this association in normal and impaired glucose tolerance patients groups.

Detailed description

We examined vascular inflammation using FDG-PET scan in 178 subjects (Normal and impaired glucose tolerance groups). Vascular 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). And We analyzed that the association with Framingham risk score, hs CRP and vascular inflammation by FDG-PET scan.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

16 Years to 80 Years

Healthy volunteers

Inclusion criteria

* healthy subjects

Exclusion criteria

* a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization) * active inflammatory disease, recent active infection * stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg) * diabetes mellitus * systemic disorders such as severe hepatic, renal, and hematologic diseases * taking drugs known to interfere with vascular inflammation measured by FDG-PET.

Countries

South Korea

Outcome results